Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Heron Therapeutics Inc (NASDAQ: HRTX) closed at $1.34 up 3.08% from its previous closing price of $1.3. In other words, the price has increased by $3.08 from its previous closing price. On the day, 1.76 million shares were traded. HRTX stock price reached its highest trading level at $1.395 during the session, while it also had its lowest trading level at $1.28.
Ratios:
For a deeper understanding of Heron Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 2.56. In the meantime, Its Debt-to-Equity ratio is 9.44 whereas as Long-Term Debt/Eq ratio is at 9.39.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on June 09, 2025, initiated with a Buy rating and assigned the stock a target price of $6.
On June 13, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $7.
On April 23, 2024, CapitalOne started tracking the stock assigning a Overweight rating and target price of $6.CapitalOne initiated its Overweight rating on April 23, 2024, with a $6 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 08 ’25 when Rubric Capital Management LP bought 2,387,225 shares for $1.50 per share. The transaction valued at 3,580,838 led to the insider holds 29,100,728 shares of the business.
Morgan Adam bought 1,766,546 shares of HRTX for $2,649,819 on Aug 08 ’25. The Director now owns 8,753,290 shares after completing the transaction at $1.50 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HRTX now has a Market Capitalization of 245705792 and an Enterprise Value of 338523776. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.58 while its Price-to-Book (P/B) ratio in mrq is 34.98. Its current Enterprise Value per Revenue stands at 2.183 whereas that against EBITDA is 85.594.
Stock Price History:
The Beta on a monthly basis for HRTX is 1.28, which has changed by -0.17721522 over the last 52 weeks, in comparison to a change of 0.13153219 over the same period for the S&P500. Over the past 52 weeks, HRTX has reached a high of $2.68, while it has fallen to a 52-week low of $1.00. The 50-Day Moving Average of the stock is 10.30%, while the 200-Day Moving Average is calculated to be -20.43%.
Shares Statistics:
For the past three months, HRTX has traded an average of 1.93M shares per day and 2198560 over the past ten days. A total of 183.32M shares are outstanding, with a floating share count of 181.64M. Insiders hold about 0.94% of the company’s shares, while institutions hold 83.72% stake in the company. Shares short for HRTX as of 1764288000 were 35966510 with a Short Ratio of 18.67, compared to 1761868800 on 34873147. Therefore, it implies a Short% of Shares Outstanding of 35966510 and a Short% of Float of 24.280001000000002.
Earnings Estimates
. The current assessment of Heron Therapeutics Inc (HRTX) involves the perspectives of 1.0 analysts closely monitoring its market dynamics.
Analysts are recommending an EPS of between -$0.05 and -$0.05 for the fiscal current year, implying an average EPS of -$0.05. EPS for the following year is -$0.05, with 1.0 analysts recommending between -$0.05 and -$0.05.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $39.83M this quarter.It ranges from a high estimate of $40.7M to a low estimate of $39.5M. As of. The current estimate, Heron Therapeutics Inc’s year-ago sales were $40.78M
A total of 4 analysts have provided revenue estimates for HRTX’s current fiscal year. The highest revenue estimate was $155M, while the lowest revenue estimate was $153.8M, resulting in an average revenue estimate of $154.15M. In the same quarter a year ago, actual revenue was $144.28MBased on 4 analysts’ estimates, the company’s revenue will be $172M in the next fiscal year. The high estimate is $174M and the low estimate is $170M.
